Clinical trial · Observational
Biomarkers in Young Patients With Neuroblastoma
Therapeutically Applicable Research to Generate Effective Treatments (TARGET) for Neuroblastoma
NCT01169376CI-TRIAL-00022252completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This research study is studying biomarkers in young patients with neuroblastoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neuroblastoma | Neuroblastoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| comparative genomic hybridization | Genetic | — | UNRESOLVED |
| DNA analysis | Genetic | — | UNRESOLVED |
| DNA methylation analysis | Genetic | — | UNRESOLVED |
| mutation analysis | Genetic | — | UNRESOLVED |
| polymorphism analysis | Genetic | — | UNRESOLVED |
| RNA analysis | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Discovery of therapeutically relevant driver mutations
Secondary outcomes (7)
- measure
- Identification of a set of neuroblastoma specimens for analyses
- measure
- Genome-wide DNA copy number and allelic status
- measure
- Genome-wide methylation profile
- measure
- Genome-wide microRNA expression profile
- measure
- Genome-wide RNA expression signatures
- measure
- Identification of mutations in candidate therapeutic targets
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 30 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Registered on the COG-ANBL00B1 Neuroblastoma Biology Study or its CCG or POG precursor
* Sufficient high-quality tumor material available for the proposed studies meeting the following criteria:
* Tissue histopathologic review with \> 70% tumor cells in sections adjacent to areas used for nucleic acid preparation
* Matched normal cells (blood or uninvolved bone marrow) available
* ≥ 5 μg DNA available
* ≥ 5 μg RNA available
* ≥ 200 mg tissue available
* Tumor samples must meet 1 of the following criteria:
* High-risk tumor
* With or without MYCN amplification
* With or without tumor progression or relapse (during ≥ 2.5 years of follow up)
* Patients aged 18 months to 5 years
* Low-risk tumor
* Primary neuroblastoma
* Stage I disease (completely resected)
* No event in ≥ 3 years of follow up
* Cell lines representing diverse high-risk genetics including with or without MYCN amplification and clinical course (at diagnosis or after relapse)
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specifiedReferences
Publications (0)
Data not yet available
No reference posted for this study.